NCT01197833View on ClinicalTrials.gov

Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities

PHASE3CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

March 31, 2012

Study Completion Date

December 31, 2012

Conditions
Great Saphenous Vein IncompetenceVisible Varicosities
Interventions
DRUG

endovenous ablation+polidocanol injectable microfoam 0.125%

All components except API

DRUG

Endovenous ablation+polidocanol injectable microfoam 1.0%

endovenous ablation to target vein, followed by injection of polidocanol injectable foam 1.0%

DRUG

Endovenous ablation+polidocanol injectable foam 2.0%

Endovenous ablation to target vein followed by injection of polidocanol injectable foam 2.0%

Trial Locations (7)

11974

Stony Brook

14120

North Tonawanda

28207

Charlotte

34209

Bradenton

60523

Oak Brook

85255

Scottsdale

98034

Kirkland

Sponsors
All Listed Sponsors
lead

Boston Scientific Corporation

INDUSTRY